Chemomab Completes Successful End-of-Phase 2 Meeting and Aligns with FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (CM-101) in Primary Sclerosing Cholangit...
Chemomab Therapeutics Ltd. - American Depositary Shares (CMMB)
Company Research
Source: GlobeNewswire
Single Positive Phase 3 Trial Designed to Support Full Regulatory Approval, For the First Time Providing Regulatory Clarity in PSC and Positioning Nebokitug to Potentially Become the First FDA-Approved Treatment for PSC No Liver Biopsies or Additional Confirmatory Studies Required—Phase 3 Trial Endpoint Is Based on Well-Characterized Clinical Events Associated with PSC Disease Progression Derisked Phase 3 Program Leverages Published PSC Data Associating Reductions in Clinical Events with the Types of Biomarker Improvements Seen in Nebokitug Phase 2 SPRING Trial Advancing Discussions with Potential Strategic Partners Post-FDA Feedback While Preparing for Nebokitug Phase 3 Trial TEL AVIV, Israel, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the successful completion of its End-of-Phase 2 M
Show less
Read more
Impact Snapshot
Event Time:
CMMB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CMMB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CMMB alerts
High impacting Chemomab Therapeutics Ltd. - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
CMMB
News
- Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of GastroenterologyGlobeNewswire
- Chemomab Therapeutics (NASDAQ:CMMB) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Chemomab to Participate in Oppenheimer’s Movers in Rare Disease SummitGlobeNewswire
- Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswire
- Chemomab Therapeutics (NASDAQ:CMMB) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.MarketBeat